Skip to main content
Caplight Logo









nChroma Bio

nChroma Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.nchromabio.com/

Last Round

Series I

Dec 11, 2024

Total Funding Raised

$435M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

nChroma Bio is a biotechnology company that develops in vivo targeted genetic medicines to treat a wide array of diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

epigenetic editinggene silencingin vivo gene therapylipid nanoparticlesLNPgenetic medicinehepatitis B cureCRISPR alternativenon-viral deliveryepigenetic therapyliver-targeted therapyHBVengineered virus-like particleseVLPclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

nChroma Bio Comparables

Compare nChroma Bio with similar companies based on industry and business-model similarity.

nChroma Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tune Therapeutics
93%
Epicrispr Biotechnologies
82%
Omega Therapeutics
80%

nChroma Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series IDec 11, 2024
Series BMar 1, 2023
Series ANov 17, 2021

Key People

Founding team and executive leadership

Padma Malyala

Chief Technology Officer

Executive Team

nChroma Bio Investors

Notable investors and investment history

nChroma Bio investors
InvestorRounds
Newpath PartnersSeed, Series B, Series A, Series I
Janus Henderson GroupSeries I, Series B, Series A
Omega FundsSeries I, Series B, Series A
GVSeries I, Seed, Series B
DCVC BioSeries I, Series B
ARCH Venture PartnersSeries I
F-Prime CapitalSeries I, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 86% MoM.

  • Jun 21, 2026

    Monthly visitors increased 65% MoM.

nChroma Bio Filings

Explore SEC and related filing metadata, where available.

nChroma Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about nChroma Bio's valuation, stock price, and market status.

Is nChroma Bio a public or private company?

nChroma Bio is a private company.

What is the current stock price of nChroma Bio?

nChroma Bio is a private company with no public stock price. No recent secondary market data is available.

How much is nChroma Bio worth (valuation)?

Valuation information for nChroma Bio is not publicly available.

Can I buy nChroma Bio stock?

nChroma Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was nChroma Bio's last funding round?

nChroma Bio's most recent funding round was Series I on December 11, 2024.

Who are the main investors in nChroma Bio?

Key investors in nChroma Bio include Newpath Partners, GV, F-Prime Capital, ARCH Venture Partners, Accomplice.

Will nChroma Bio IPO soon?

No public IPO plans have been announced for nChroma Bio.

How can I track nChroma Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor nChroma Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range55
Year Founded2024
Last FundingDec 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?